White cell and platelet content affects the release of bioactive factors in different blood-derived scaffolds
Cabaro, S., D'Esposito, V., Gasparro, R., Borriello, F., Granata, F., Mosca, G., Passaretti, F., Sammartino, J. C., Beguinot, F., Sammartino, G., Formisano, P., Riccitiello, F.
Published in Platelets (Edinburgh) (04.07.2018)
Published in Platelets (Edinburgh) (04.07.2018)
Get full text
Journal Article
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Cicognini, D., Schiavo, R., Lo Cascio, G., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Lilleri, D., Secondino, S., Falzoni, M., Schiavo, R., Klersy, C., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Published in ESMO open (01.10.2021)
Published in ESMO open (01.10.2021)
Get full text
Journal Article
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Published in ESMO open (01.04.2022)
Published in ESMO open (01.04.2022)
Get full text
Journal Article
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Serra, F., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Published in ESMO open (01.10.2022)
Published in ESMO open (01.10.2022)
Get full text
Journal Article
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Secondino, S., Falzoni, M., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Published in ESMO open (01.02.2022)
Published in ESMO open (01.02.2022)
Get full text
Journal Article